ArticleCureus2026
Peliosis Hepatis Presenting As Pseudometastatic Liver Lesions During Adjuvant Therapy for Colon Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peliosis hepatis (PH) is a rare benign vascular liver disorder that may closely mimic hepatic metastases on imaging, posing a significant diagnostic challenge in oncology. We report the case of a 54-year-old patient with left-sided nonmetastatic colon adenocarcinoma (pT4N0) treated surgically and receiving adjuvant Folinic acid, Fluorouracil, and Oxaliplatin chemotherapy for high-risk pathological features. During follow-up, contrast-enhanced computed tomography revealed a dysmorphic liver with a thin-walled lesion in segments II-III, highly suspicious for secondary hepatic involvement in the oncological context. A multidisciplinary decision led to a left hepatic lobectomy, and histopathological examination demonstrated PH, characterized by dilated congestive sinusoids and intraparenchymal hemorrhage, with preserved hepatic architecture and no evidence of malignancy or cirrhosis. Adjuvant chemotherapy was subsequently resumed and completed over a total of six months, with good tolerance. At the last follow-up, the patient showed no clinical, biological, or radiological evidence of disease recurrence. This case emphasizes the importance of including PH in the differential diagnosis of atypical hepatic lesions during oxaliplatin-based chemotherapy to avoid overstaging and unnecessary treatment modification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.